Synergy Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing drugs for treating gastrointestinal (GI) disorders and diseases. Synergy’s lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist which has completed Phase IIa clinical trials for the … Continue reading →

Prima BioMed Ltd. is a biotechnology company researching and developing licensed medical biotechnology products in Australia. The company’s lead product is CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. The company is also … Continue reading →

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on the discovery, acquisition, development and commercialization of proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. In addition to developing StemScreen platform technology for the identification of novel … Continue reading →

Rosetta Genomics Ltd. develops diagnostic tools for microRNAs, a group of genes produced using instructions encoded in DNA. The company offers diagnostic tests, including miRview mets2, a microRNA-based diagnostic used to identify 42 tumor types including carcinomas, soft tissue tumors, … Continue reading →

AtheroNova Inc. is a development stage company engaging in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. The company develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, the primary … Continue reading →

Opexa Therapeutics, Inc. is a biopharmaceutical company that develops personalized cellular therapies to treat multiple sclerosis (MS) using its proprietary T-cell technology. Its leading therapy candidate includes Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for … Continue reading →

OHR Pharmaceutical, Inc. is a biotechnology company. The company’s products include Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism that inhibits vascular endothelial, platelet derived and basic fibroblast growth factors to treat the wet form of age-related macular … Continue reading →

PharmAthene, Inc. is a biodefense company developing medical countermeasures against biological and chemical threats. The company’s product candidates include: SparVax, an anthrax vaccine which has completed a Phase II clinical trial for post-exposure prophylaxis; Valortim, a human monoclonal antibody which … Continue reading →

Mast Therapeutics, Inc. (NYSE: MSTX) is a biopharmaceutical company developing therapies for life-threatening diseases. The company’s lead product candidate is MST-188, which has hemorheologic, cytoprotective, and anti-inflammatory properties and is in phase 3 study for the treatment of sickle cell … Continue reading →

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company developing prescription drugs targeting rare neuromuscular and neurological diseases and disorders. The company’s principal product is Firdapse, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. … Continue reading →